Oct. 22 at 8:28 PM
$CRDF Article talks about release coming!! What to Expect During the Q3 Update
In the Q3 2025 update, Cardiff Oncology is expected to release new clinical data from its Phase 2 CRDF-004 trial for RAS-mutated metastatic colorectal cancer. I anticipate that this update will probably focus on efficacy signals, safety outcomes, and durability of response for onvansertib combined with standard therapy.